FDA Approved: JYNARQUE — Original Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

The FDA approved JYNARQUE (tolvaptan) from Otsuka for autosomal dominant polycystic kidney disease, marking the first drug approved to slow disease progression …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• JYNARQUE (tolvaptan)

Snippet

ORIG AP for JYNARQUE (TOLVAPTAN)